To enhance India’s biosimilar market and support complete indigenous development of biosimilars, (therapeutic proteins and monoclonal antibodies) National Biopharma Mission is supporting the development of clones preferably for those biosimilars with innovator patent expiry (US/EU) between 2020-2025.
|
Therapeutic Area/ Name of Product |
Name of grantee |
Development Phase Supported |
Environmental and Health Risk Management Plan (EHRMP) |
| Cancer/Ramucirumab | Enzene Biosciences Ltd | Clone Development | Click Here |
| Cancer/Golimumab | Genext Genomics Pvt Ltd | Clone Development | Click Here |
| Emergency Situations/Factor VIII | Vellore Institute of Technology & Amthera Lifesciences Pvt Ltd | Clone Development |